Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ12,14PGJ2

Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ^12,14PGJ₂ a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ^12,14PGJ₂ production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ₂ and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment.     

Erythema induratum of Bazin in a 10‐year‐old boy

Erythema induratum of Bazin (EIB) is a form of tuberculid resulting from hypersensitivity to tuberculosis antigen. EIB occurs most commonly in middle‐aged women and is not typically seen in children. Here, we present a rare case of EIB, presenting as a chronic nodular panniculitis, in a 10‐year‐old Korean boy.     

Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends

In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis.     

TSo联合IFN-γ鼻内免疫小鼠诱导的弓形虫IgA抗体特异性免疫应答

目的研究速殖子超声裂解物(TSo)和IFN-γ鼻内免疫小鼠经口感染弓形虫速殖子后,血清、小肠液和粪便IgA抗体分泌的动态变化。方法将6～7周龄BALB/c小鼠100只随机分为4组,每组25只,分别用10μl缓冲液PBS、20μgTSo、500UIFN-γ和20μgTSo 500UIFN-γ鼻内免疫小鼠。用RH株弓形虫速殖子4×104个/只灌胃攻击,分别于攻击后第7、10、13、16、19天处死小鼠,收集血清、小肠液及粪便,ELISA法测定IgA含量。结果各组血清IgA抗体水平在攻击后第10天达到峰值,TSo IFN-γ组血清IgA抗体含量高于其他各组。小肠液和粪便IgA抗体含量在攻击后第13天达到峰值,在实验期各时点TSo IFN-γ组小肠液和粪便IgA抗体含量高于其他组。小肠液与粪便IgA抗体水平呈正相关。结论TSo或IFN-γ或TSo联合IFN-γ鼻内免疫小鼠可诱导黏膜免疫,产生高水平的弓形虫特异性IgA抗体。TSo联合IFN-γ鼻内免疫优于单独免疫,免疫小鼠肠道产生大量SIgA,发挥抗虫作用。鼻黏膜免疫是一种安全有效的免疫接种途径。     

胰岛素增敏剂曲格列酮对人卵巢颗粒细胞芳香化酶活性的抑制作用

为探讨曲格列酮(troglitazone,TGZ)对人卵巢颗粒细胞芳香化酶(P450arom)活性的调节作用，以不同剂量的TGZ和(或)维甲酸类X受体(RXR)激动剂(LG100268，LG)处理来源于体外受精患者的卵巢颗粒细胞24h，然后测定细胞的芳香化酶活性和P450arom mRNA水平。结果发现，TGZ处理颗粒细胞24h可引起剂量依赖性的芳香化酶活性下降；LG单独作用可以抑制芳香化酶活性，但与TGZ合用对芳香化酶的抑制作用更明显；RT-PCR结果显示，随着芳香化酶活性的下降，P450arom mRNA表达水平也降低。表明TGZ可能是通过过氧化物酶体增殖物激活受体γ(PPARγ)：RXR异二聚体组成的核受体系统直接抑制卵巢颗粒细胞芳香化酶活性。